Insulin resistance and overweight-obese women with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 26, Issue 5, 2010, Pages 344-347

  Bhattacharya, Sudhindra Mohan ^a,b  

^a S C das Memorial Medical and Research Center   (India)

^b VIVEKANANDA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Insulin resistance; Obesity; Polycystic ovary syndrome

Indexed keywords

GLUCOSE; INSULIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ACANTHOSIS NIGRICANS; ACNE; ADULT; ARTICLE; BIOCHEMISTRY; BODY MASS; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HIRSUTISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; WAIST CIRCUMFERENCE;

ACANTHOSIS NIGRICANS; ADOLESCENT; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; FASTING; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; OBESITY; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; WAIST CIRCUMFERENCE;

EID: 77951096705     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590903367002     Document Type: Article

References (22)

1. American Diabetes Association. Consensus development conference on insulin resistance. Diabetes Care 1997;21: 310-314.
2. DeFronzo RA, Tobin JD, Andres R. Glucose-clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223.
3. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83: 2694-2698.
4. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovary syndrome. J Clin Endocrinol Metab 1983;57:356-359.
5. Dunaif A, Segal KR, Shelly DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41: 1257-1266.
6. Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;9:41-47.
7. World Health Organisation. The Asia-Pacific perspective: redefining obesity and its treatment. Geneva: WHO; 2000.
8. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for Type 2 diabetes mellitus and IGT in polycystic ovary syndrome: a prospective controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169.
9. Lewis V. Polycystic ovary syndrome: a diagnostic challenge. Infert Reprod Med Clin N Am 2003;14:497-516.
10. Gennavelli G, Holte J, Berglund L, Berne C, Massobrio M, Lithell H. Prediction model for insulin resistance in the polycystic ovary syndrome. Hum Reprod 2000;15:2098-2102.
11. Morin-Papunen LC, Vauhkomen I, Koivumen RM, Rouokomen A, Tapanaimen JS. Insulin sensitivity, insulin secretion and metabolic and hormonal parameters in healthy women and women with polycystic ovary syndrome. Hum Reprod 2000;15:1266-1274.
12. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
13. Ovesen P, Moller J, Ingerslev HJ, Jorgensen JO, Mengel A, Schmitz O, Alberti KG, Moller N. Normal basal and insulin stimulated fuel metabolism. J Clin Endocrinol Metab 1993; 77:1636-1640.
14. Holte J. Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with overfeeding and sedentary life style? J Endocrinol Invest 1998;21:589-602.
15. Vrbikova J, Bend Lova B, Hill M, Vankova M, Vondra Y, Starka L. Insulin sensitivity and beta cell function in women with polycystic ovary syndrome. Diabetes Care 2002;25:1217-1222. (Pubitemid 41071175)
16. Nesto R. C-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease and the effects of insulinsensitising treatment with thiazolidinediones. Diabetes Med 2004;21:810-817.
17. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids and ectopic fat in the pathogenesis of type 2 diabetes mellitus: peroxisome proliferators-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004;89:463-478.
18. Hsuch WA, Lyon CJ, Quinones MJ. Insulin resistance and the endothelium. Am J Med 2004;117:109-117.
19. Masuzaki H, Flier JS. Tissue-specific glucocorticoid reactivating enzyme, 11-beta-hydroxysteroid dehydrogenase type 1- a promising drug target for the treatment of metabolic syndrome. Curr Drug Targets Immune Endocrinol Metab Disord 2003;3:255-262.
20. Stuart CA, Gilkison CR, Smith MM, Bosna AM, Keenan BS, Nagamani M. Acanthosis Nigricans as a risk factor for noninsulin dependent diabetes mellitus. Clin Paediatr 1998;37: 73-80.
21. Stoddart ML, Blevins KS, Lee ET, Wang W, Blackett PR. Association of Acanthosis Nigricans with hyperinsulinaemia compared with other selected risk factors for type 2 diabetes in Cherokee Indians. Diabetes Care 2002;25:1009-1014.
22. Acien P, Quereda F, Matallin P, Villarroya E, Lopaz-Fernandez JA, Acien M, Mauri Monserrat, Alfayate R. Insulin, androgens and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999;72:32-40.